REDWOOD CITY, Calif.,
Nov. 30, 2017 /PRNewswire/
-- Genomic Health, Inc. (NASDAQ: GHDX) today
announced that it will present 10 Oncotype
DX® studies at the 40th San Antonio
Breast Cancer Symposium (SABCS), which is being held December
5-9, 2017. Presentation highlights include:
- Positive results from an international validation study
analyzing the utility of the Oncotype DX Breast Recurrence
Score® test in predicting clinical response to endocrine
therapy in the neoadjuvant setting to improve surgical outcomes in
postmenopausal patients with estrogen-positive early-stage breast
cancer.
- Assessment of clinical outcomes in patients with low-risk
breast cancer as defined by the new 8th edition AJCC Staging
Manual.
- A separate SEER Registry analysis that evaluated the clinical
utility of the Oncotype DX Breast Recurrence Score® test
in guiding chemotherapy treatment decisions in node-positive breast
cancer.
- Additional data supporting use of the Oncotype DX®
Breast DCIS Score™ test, along with tumor size and
patient age, to determine risk of local recurrence and guide
individual decision making for DCIS patients.
Abstracts are now available at www.sabcs.org. Complete results
from these studies will be announced during SABCS in accordance
with the meeting embargo policy. Following are details for each
presentation (all times are in Central Standard Time):
Wednesday, December 6
- Abstract: OT1-06-02
Poster: "Oncotype DX-REMAR Study: Use of the Oncotype DX assay in
early breast cancer in certified breast cancer centers in
Rhine-Main Region, Germany"
Authors: Anastasiadou L, Aulmann S, Falk S, Baier P, Giesecke D,
Buchen S, Hurst U, Krapfl E, Moebus V, Mosch D, Schulmeyer E,
Solbach C, Ackermann S, Gabriel B, Jackisch C.
Location: Hall 1
Time: 5-7 p.m.
- Abstract: P1-06-03
Poster: "Breast cancer-specific survival in SEER patients with
21-gene Recurrence Score® results <11 classified as
prognostic stage IA by new 8th edition AJCC Staging Manual"
Authors: Baehner FL, Petkov VI, McCullough D, Shak S.
Location: Hall 1
Time: 5-7 p.m.
- Abstract: P1-06-06
Poster: "No age-related outcome disparities according to 21-gene
Recurrence Score groups in early breast cancer patients treated by
adjuvant chemotherapy in the prospective WSG PlanB trial"
Authors: Harbeck N, Gluz O, Wuerstlein R, Clemens M, Malter W,
Reimer T, Nuding B, Stefek A, Pollmanns A, Augustin D,
Lorenz-Salehi F, Shak S, Chao C, Christgen M, Kates R, Kreipe H,
Nitz U.
Location: Hall 1
Time: 5-7 p.m.
- Abstract: P1-07-14
Poster: "Real life analysis evaluating >1000 N0/N1mi ER+ breast
cancer patients for whom treatment decisions incorporated the
21-gene Recurrence Score result: Clinical outcomes with median
follow up of >9 years"
Authors: Stemmer SM, Rizel S, Steiner M, Geffen DB, Soussan-Gutman
L, Bareket-Samish A, McCullough D, Svedman C, Nisenbaum B, Ryvo L,
Peretz T, Fried G, Rosengarten O, Liebermann N, Ben Baruch N.
Location: Hall 1
Time: 5-7 p.m.
Thursday, December 7
- Abstract: P2-05-15
Poster: "Oncotype DX Breast Recurrence Score: Real-life utilization
among node-positive patients in Ontario clinical practice"
Authors: Richardson R, Macchiusi A, Bhasin A, Takizawa C.
Location: Hall 1
Time: 7-9 a.m.
- Abstract: PD5-03
Poster: "TransNEOS: Validation of the Oncotype DX Recurrence Score
testing core needle biopsy samples from NEOS as predictor of
clinical response to neoadjuvant endocrine therapy for
postmenopausal ER+, HER2-negative breast cancer patients"
Authors: Yamamoto Y, Iwata H, Masuda N, Fujisawa T, Toyama T,
Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R,
Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Chao C,
McCullough D, Sugiyama N, Ohashi Y
Location: Stars at Night Ballroom 1&2 - 3rd Level
Time: 5-7 p.m.
Friday, December 8
- Abstract: P4-15-08
Poster: "Association of Oncotype DX DCIS Score results with local
recurrence in patients with DCIS treated on accelerated partial
breast radiotherapy protocols"
Authors: Leonard CE, Fryman SP, Turner MP, Bennett JP, Carter DL, Sing AP.
Location: Hall 1
Time: 7-9 a.m.
- Abstract: P4-15-09
Poster: "Refined estimates of local recurrence risk in a clinical
utility study: Integrating the DCIS score, patient age and DCIS
tumor size"
Authors: Manders JB, Solin LJ, Leonard CE, Mamounas EP, Lu R,
Turner M, Baehner FL, White J.
Location: Hall 1
Time: 7-9 a.m.
- Abstract: PD7-13
Poster: "Molecular Characterization and Mortality from Breast
Cancer in Men"
Authors: Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov
VI, Shak S.
Location: Stars at Night Ballroom 1&2
Time: 7-9 a.m.
Saturday, December 9
- Abstract: P6-13-03
Poster: "Breast cancer-specific mortality in patients with N+
breast cancer treated based on the 21-gene assay in clinical
practice"
Authors: Shak S, McCullough D, Petkov VI.
Location: Hall 1
Time: 7-9 a.m.
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer
tests applies advanced genomic science to reveal the unique biology
of a tumor in order to optimize cancer treatment decisions. The
company's flagship product, the Oncotype DX Breast Recurrence
Score® test, has been shown to predict the likelihood of
chemotherapy benefit as well as recurrence in invasive breast
cancer. Additionally, the Oncotype DX Breast DCIS Score™ test
predicts the likelihood of recurrence in a pre-invasive form of
breast cancer called DCIS. In prostate cancer, the Oncotype DX
Genomic Prostate Score™ test predicts disease aggressiveness and
further clarifies the current and future risk of the cancer prior
to treatment intervention. With more than 800,000 patients tested
in more than 90 countries, the Oncotype DX tests have redefined
personalized medicine by making genomics a critical part of cancer
diagnosis and treatment. To learn more about Oncotype DX tests,
visit
www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care, including
addressing the overtreatment of the disease, one of the greatest
issues in healthcare today. With its Oncotype
IQ® Genomic Intelligence Platform, the company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic big
data into actionable results for treatment planning throughout the
cancer patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype
DX® gene expression tests that have been used to
guide treatment decisions for more than 800,000 cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
recently launched Oncotype SEQ® Liquid
Select™ test. The company is based in Redwood
City, California, with international headquarters in
Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits of our tests to
physicians, patients and payors. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the ability of our
test results to change treatment decisions; the risks and
uncertainties associated with the regulation of the company's
tests; the results of clinical studies; the applicability of
clinical study results to actual outcomes; the risk that the
company may not obtain or maintain sufficient levels of
reimbursement, domestically or abroad, for its existing tests and
any future tests it may develop; the risks of competition;
unanticipated costs or delays in research and development efforts;
and the other risks set forth in the company's filings with the
Securities and Exchange Commission, including the risks set forth
in the company's quarterly report on Form 10-Q for the quarter
ended September 30, 2017. These
forward-looking statements speak only as of the date hereof.
Genomic Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, DCIS Score, Oncotype SEQ, Liquid Select, Genomic
Prostate Score, Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ
are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their
respective owners.
GHDX-B
View original content with
multimedia:http://www.prnewswire.com/news-releases/genomic-health-announces-presentation-of-10-oncotype-dx-studies-at-the-2017-san-antonio-breast-cancer-symposium-demonstrating-tests-unique-value-in-predicting-neoadjuvant-treatment-benefit-and-guiding-breast-cancer-staging-300564052.html
SOURCE Genomic Health, Inc.